| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2/3 topline data readout example | Phase 2/3 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2/3 topline data readout example | Phase 2/3 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2/3 topline data readout example | Phase 2/3 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Biohaven Ltd.$15.55
-1.24 (-7.39%)
C 56Pipeline Score Fair Value Pharma · Commercial
Market Cap
1.55 B
EPS
-5.67
P/E Ratio
-1.82 $
Value Trade
33.09 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
103.83 M
Operating CF
-149.92 M
Total Assets
466.41 M
Total Liabilities
336.91 M
Equity
129.50 M
D/E Ratio
12,345
6.18 %
Week
-7.89 %
1 Month
-15.47 %
3 Month
-1.97 %
6 Month
57.5 %
5 Year
57.5 %
All Time
Cash Data
Cash Position
347.82 M
Monthly Burn
49.97 M
Runway
4.7 mo
Burn Trend
StableSEC Filing
May 4, 2026
Overview
Volume
2.13 M
52 Week Range
7.48 - 18.57
% held by Insiders
16.68 %
% held by Institutions
91.78 %
Enterprise Value
1.49 B
Total Shares
150.54 M
Short %
17.15 %
Float Shares
119.38 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Biohaven Ltd.
295Total events
5Upcoming
82Tier-1 (high impact)
2022 – 2027Coverage
Upcoming catalysts 5
2027
T2Pipeline Prioritization
Anticipate delivering approximately ten clinical-stage degraders over next three years
Event history 290
Q3 2026
Q3 2026
◆Topline ReadoutOpakalimClinical Data
Top-line results from RISE3 expected in 2H 2026
refractory focal epilepsysource ↗
Jun 30, 2026
▲Enrollment CompleteOpakalimTrial
Enrollment completed in pivotal Phase 2/3 study RISE3 for opakalim in focal epilepsy
refractory focal epilepsysource ↗
Jun 29, 2026
▲First Patient DosedBHV-1300Trial
First patient enrolled in pivotal Phase 3 trial of BHV-1300 for Graves' disease
Graves' diseasesource ↗
Jun 29, 2026
▲Trial InitiationBHV-1300Trial
Pivotal Phase 3 trial initiated for BHV-1300 in Graves' disease
Graves' diseasesource ↗
Jun 1, 2026
▲First Patient DosedBHV-8100Trial
First-in-human dosing initiated for BHV-8100
healthy participantssource ↗
Jun 2026
◆Trial InitiationBHV-1300Trial
Initiation of pivotal trial for BHV-1300 in Graves' disease
Graves' diseasesource ↗
Jun 2026
◆Trial InitiationBHV-1400Trial
Initiation of pivotal trial for BHV-1400 in IgA nephropathy
IgA nephropathysource ↗
May 27, 2026
May 27, 2026
▲Biomarker DataBHV-1300Clinical Data
Positive clinical biomarker and patient data for BHV-1300 in Graves' disease
Graves' diseasesource ↗
May 27, 2026
▲Biomarker DataBHV-1400Clinical Data
Positive clinical biomarker and patient data for BHV-1400 in IgA nephropathy
IgA nephropathysource ↗
Drug Pipeline Intelligence
C56
Pipeline Score $1.3B
Pipeline ValueFair Value
Valuation Signal15
Drugs Scored0.8x
rNPV / MCap Top 84%
Micro Cap (rank 147 of 912)
Percentile RankBiohaven Ltd. carries a moderate pipeline score (56/100), with $6.5B risk-adjusted pipeline value, led by Taldefgrobep Alfa in Obesity (Phase 2), across $148B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| taldefgrobep alfa Small molecule | Spinal Muscular Atrophy | Phase 3 | NCT05337553 | 60% | $2.0B | ACTIVE NOT_RECRUITING | 269 | FAST | B (73) | Dec 1, 2027 | LOW_RISK | MEDIUM Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
opakalim | focal epilepsy | Phase 2/3 | 2026-06-30 | 54% of participants experienced significant reductions in seizure frequency Read More | Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator Read More | |
opakalim | focal epilepsy | Phase 2/3 | 2026-06-30 | 54% of participants experienced significant reductions in seizure frequency Read More | Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator Read More | |
opakalim | focal epilepsy | Phase 2/3 | 2026-06-30 | 54% of participants experienced significant reductions in seizure frequency Read More | Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BHVN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BHVN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BHVN▼ -7.4%on this news
Biohaven Announces Scientific Leadership Transitions
Biohaven Ltd. has announced key leadership transitions aimed at enhancing drug innovation and collaborations. David Pirman has been promoted to Executive Vice President and Head of Discovery, while Bruce Car transitions to Chief Innovation Officer, focusing on external partnerships. Warren Volles has also been designated as an executive officer, continuing his legal leadership at the company.
Read more →BHVNBiohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
Biohaven has completed enrollment in its pivotal Phase 2/3 study, RISE3, evaluating opakalim for focal epilepsy. The study aims to provide top-line results in the second half of 2026. Preliminary data shows that 54% of participants experienced significant reductions in seizure frequency, with a favorable safety profile. The company emphasizes the need for new treatments for patients with uncontrolled seizures.
Read more →BHVN▼ -5.6%on this newsshared move
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Biohaven has initiated a pivotal Phase 3 trial for BHV-1300, the first MoDE extracellular protein degrader targeting Graves' disease. This innovative therapy aims to eliminate the disease-driving TSHR-IgG1 autoantibody rather than just treating symptoms. The trial represents a significant advancement in precision immunology, with potential implications for treating autoimmune diseases more effectively.
Read more →BHVNBiohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis...
Biohaven has announced the initiation of first-in-human dosing for BHV-8100, a novel oral pyruvate kinase M2 modulator designed to target metabolic and immune dysfunction. The drug aims to improve energy homeostasis in patients suffering from various neurodegenerative and retinal diseases. Effective in enhancing ATP generation, BHV-8100 was validated through preclinical testing, and a Phase 1 study has begun in healthy participants to assess its safety and pharmacokinetics. The company believes this treatment could provide significant benefits for patients with conditions such as Alzheimer's disease and retinitis pigmentosa.
Read more →BHVN▲ +12.1%on this newsshared move
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
Biohaven Ltd. has announced positive results from its clinical trials involving its proprietary MoDE and TRAP degrader platforms. The data, presented at the 2026 Yale Innovation Summit, highlights the effectiveness of BHV-1300 in treating Graves' disease and BHV-1400 for IgA nephropathy. These findings suggest significant advancements in the treatment of autoimmune diseases.
Read more →BHVN▲ +12.1%on this newsshared move
About Biohaven Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.
Biohaven has reported promising new clinical data on opakalim, a selective Kv7.2 7.3 channel activator, for treating epilepsy. In a randomized trial for idiopathic generalized epilepsy, opakalim demonstrated a three-fold increase in the median time to the second seizure compared to placebo. An ongoing open-label extension study showed favorable results for patients with focal epilepsy, with over 54% achieving a significant reduction in seizure frequency. Opakalim's tolerability profile is notably better than other antiseizure therapies, with a low incidence of adverse central nervous system events.
Read more →BHVN▲ +6.6%on this news· ran to +19% by day 1shared move
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a...
Biohaven Ltd. has reported new clinical data for Opakalim, a selective Kv7.2/7.3 channel activator, demonstrating promising results in seizure control for idiopathic generalized epilepsy (IGE). The treatment offers a favorable tolerability profile, showing zero rates of common central nervous system side effects reported with other antiseizure medications. Additionally, high completion rates in ongoing studies reflect strong confidence among participants. However, challenges with enrollment have prevented reaching the intended study sample size, raising questions about the robustness of the findings.
Read more →BHVNBiohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Biohaven Ltd. reported its Q1 2026 financial results, highlighting plans for pivotal clinical trials for BHV-1300 and BHV-1400. The company aims to advance its innovative therapies in immunology, neuroscience, and oncology. Despite a net loss of $130.5 million, Biohaven shows optimism with strategic milestones and reduced R&D expenses.
Read more →BHVNBiohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline...
Biohaven has announced that enrollment for its Phase 2 study of taldefgrobep alfa, a myostatin-activin pathway inhibitor for obesity, has been completed. The study is designed to evaluate the efficacy and tolerability of the drug administered as once-weekly and once-monthly doses. Topline data from this proof-of-concept study is anticipated in the second half of 2026. Previous studies have shown that taldefgrobep can reduce body fat and increase lean muscle mass, suggesting it may be an important treatment option in managing obesity.
Read more →BHVN▼ -9.7%on this news
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
Biohaven Ltd. reported its financial results for Q4 and full year 2025, highlighting advancements in its therapeutic pipeline, particularly in immunology and epilepsy treatments. The company emphasized its innovative degrader platform and promising data from its Kv7 program for focal epilepsy. Despite significant losses, Biohaven is focused on strategic cost optimization and prioritizing late-stage clinical programs.
Read more →BHVN▲ +6.6%on this news
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary...
Biohaven Ltd. showcased its progress and positive early patient data at the 44th Annual J.P. Morgan Healthcare Conference. The company reported successful initial dosing in its obesity program with a dual-action therapy and highlighted early clinical results from its BHV-1400 degrader for IgA nephropathy, showing rapid symptom resolution. Additionally, BHV-1300 exhibited significant reductions in IgG for Graves' disease. Biohaven is set to advance multiple programs targeting high unmet needs in 2026.
Read more →BHVN▲ +22%on this newsshared move
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
Biohaven Ltd. has announced that its CEO, Vlad Coric, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The conference will take place at The Westin St. Francis Hotel in San Francisco. Biohaven is known for its focus on developing treatments in various therapeutic areas, including immunology and oncology.
Read more →BHVNBiohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
Biohaven Ltd. reported results from a Phase 2 study of BHV-7000 for major depressive disorder. The study failed to meet its primary endpoint, showing no significant reduction in depressive symptoms compared to placebo. However, some trends were noted in specific subgroups with more severe depression. The company plans to focus resources on other therapeutic areas moving forward.
Read more →BHVN▲ +7.9%on this news
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
Biohaven presented clinical data for BHV-1510 at the 2025 ESMO Immuno-Oncology Congress, showcasing its efficacy in combination with cemiplimab. The therapy demonstrated a confirmed objective response rate of 52.2% across various tumors, with notable results in endometrial cancer. The treatment was generally well tolerated, with manageable side effects. These findings suggest potential for BHV-1510 in earlier lines of therapy.
Read more →BHVNBiohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
Biohaven Ltd. has announced the successful closing of its upsized public offering, raising approximately $200 million through the sale of 26,833,334 common shares. This includes the full exercise of the underwriters' option to purchase additional shares. The company plans to utilize the net proceeds for general corporate purposes, reflecting a positive outlook for its operations.
Read more →BHVN▼ -6.7%on this newsshared move
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
Biohaven Ltd. has announced the pricing of its public offering of 23,333,334 common shares at $7.50 each, aiming to raise approximately $175 million. The offering is expected to close on November 13, 2025, pending customary conditions. Biohaven plans to use the proceeds for general corporate purposes.
Read more →BHVN▼ -6.7%on this newsshared move
Biohaven Announces Proposed Public Offering of Common Shares
Biohaven Ltd. has announced a proposed public offering of $150 million in common shares, with an additional option for underwriters to purchase $22.5 million more. The proceeds will be used for general corporate purposes. The offering is contingent on market conditions, and there is uncertainty regarding its completion and terms.
Read more →BHVN▼ -5.7%on this newsshared move
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
Biohaven Ltd. reported its third quarter 2025 financial results, highlighting a net loss of $173.4 million. The company remains focused on advancing its innovative therapies across various medical conditions. CEO Vlad Coric emphasized the potential of their clinical-stage assets and the importance of a strategic approach to resource allocation. Despite the financial losses, Biohaven is optimistic about its future milestones and ongoing projects.
Read more →BHVN▼ -40.2%on this newsshared move
FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
Biohaven Ltd. has received a Complete Response Letter from the FDA regarding its New Drug Application for VYGLXIA (troriluzole), intended for the treatment of spinocerebellar ataxia. This indicates that the FDA has not approved the drug at this time, which could impact the availability of treatment for patients suffering from this condition. The company will need to address the FDA's concerns before resubmitting the application.
Read more →BHVN▼ -9%on this news
Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments Cash, cash equivalents, marketable securities and restricted cash as of
Biohaven Ltd. reported financial results for the second quarter of 2025, highlighting approximately $408.2 million in liquidity. The company is advancing several clinical programs, notably the VYGLXIA NDA for spinocerebellar ataxia, which is under ongoing review with a PDUFA date scheduled for the fourth quarter of 2025. Additionally, promising results were reported for their MoDE and TRAP degrader platforms and the new antibody-drug conjugate BHV-1510, which showed tumor reduction in all patients treated. Biohaven remains focused on addressing unmet medical needs across multiple therapeutic areas, including neurological and oncology indications.
Read more →BHVN▼ -9%on this news
Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments Cash, cash equivalents, marketable securities and restricted cash as of June 30, 2025, totaled approximately $408.2 million VYGLXIA NDA for...
Biohaven Ltd. reported its Q2 2025 financial results, highlighting a cash position of approximately $408.2 million. The company is awaiting a regulatory decision on the VYGLXIA NDA for spinocerebellar ataxia, with a PDUFA date set for Q4 2025. Several clinical programs are advancing, including promising results from BHV-1510 and BHV-8000. However, the company also reported a significant net loss and terminated its OCD program due to lack of efficacy.
Read more →BHVNBiohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor
Biohaven Ltd. has commenced a global Phase 2/3 trial for BHV-8000, a novel TYK2/JAK1 inhibitor aimed at treating early Parkinson's disease. This pivotal study will evaluate the efficacy and safety of BHV-8000 compared to placebo, enrolling 550 patients across 13 countries. The trial's design includes innovative endpoints to assess meaningful changes in patient function.
Read more →BHVNBiohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)
Biohaven Ltd. announced significant advancements in its TRAP and MoDE degrader platforms during its R&D Day. The TRAP degrader BHV-1400 achieved over 80% sustained reductions in galactose-deficient IgA1, showing promise for treating IgA nephropathy. The company plans to initiate pivotal trials for BHV-1400 in 2026 and BHV-1300 for Graves' Disease in 2025.
Read more →BHVNBiohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors
Biohaven Ltd. presented updates on its oncology programs, highlighting promising preliminary data for its Trop2-directed ADC, BHV-1510, which showed encouraging activity both alone and with cemiplimab. The company also initiated a Phase 1 study for BHV-1530, an FGFR3-directed ADC. Both therapies demonstrate potential to address unmet needs in oncology.
Read more →BHVN▼ -19.5%on this news
sections titled Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations . The forward-looking statements are made as of the date of this news release, and Biohaven does not
Biohaven Ltd. announced that the FDA has extended the PDUFA date for the new drug application (NDA) for Troriluzole, a treatment for spinocerebellar ataxia (SCA), by three months to ensure a comprehensive review of new information submitted. No new concerns were raised by the FDA, and the potential approval of Troriluzole could provide the first and only treatment option for this rare, neurodegenerative disease. The FDA is also planning an advisory committee meeting to discuss the NDA, scheduled for later this year.
Read more →BHVNFDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced that the Division of Neurology 1 within FDA's Office of Neuroscience informed...
Biohaven Ltd. has announced an extension of the FDA's PDUFA date for its New Drug Application (NDA) for Troriluzole, aimed at treating the rare and life-threatening disease Spinocerebellar Ataxia (SCA). The FDA has granted Troriluzole Fast-Track, Orphan Drug Designation, and Priority Review, signaling its potential to be the first approved treatment for SCA. Clinical data supports a promising benefit-risk profile, showing significant slowing of disease progression. The announcement follows a successful mid-cycle review where no major safety concerns were found, leading to optimism among stakeholders about the potential approval of Troriluzole.
Read more →BHVNBiohaven Reports First Quarter 2025 Financial Results and Recent Business Developments Cash, cash equivalents, marketable securities and restricted cash as of April 30, 2025 totaled approximately $518 million. Announced up to $600...
Biohaven Ltd. reported its first quarter 2025 financial results, highlighting a cash position of approximately $518 million and a strategic focus on advancing several clinical trials. The company is eagerly awaiting the completion of its NDA review for troriluzole, while also preparing to initiate multiple Phase 1 studies for new compounds targeting various conditions. Despite the positive developments, Biohaven continues to experience net losses, raising concerns about financial sustainability during a challenging economic landscape.
Read more →BHVN▲ +9.6%on this news
expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials the timing of planned interactions and filings with the FDA the timing and outcome of expected regulatory filings complying wit
Biohaven Ltd. has announced an agreement with Oberland Capital Management for an investment of up to $600 million, aimed at supporting ongoing clinical trials and commercialization efforts for their product, troriluzole. The first $250 million will be funded at closing, with potential further funding contingent on regulatory milestones. This investment is expected to assist in the treatment development for patients with spinocerebellar ataxia, a group of rare genetic conditions with no current treatments available. The funding agreement is non-dilutive to current investors and includes milestone payments and royalties on future sales.
Read more →BHVN▲ +9.6%on this news
Biohaven Announces Investment up to $600 Million by Oberland Capital Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and...
Biohaven Ltd. has announced a significant investment agreement with Oberland Capital for up to $600 million, aimed at supporting ongoing clinical trials and commercialization efforts, particularly for the drug troriluzole targeting spinocerebellar ataxia. The initial $250 million will be funded by the end of April 2025, with further tranches contingent on regulatory approval. This long-term, non-dilutive financing is expected to bolster Biohaven's development portfolio across various therapeutic areas. Executives from both companies expressed enthusiasm over the collaboration and the potential impact on rare disease treatments.
Read more →BHVNBiohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting Biohaven Ltd. (NYSE: BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking...
Biohaven Ltd. announced the presentation of 13 abstracts at the 2025 American Academy of Neurology Annual Meeting. The presentations will cover various aspects of its neuroscience pipeline, including new treatments for neuroinflammatory and neurodegenerative diseases. The company aims to highlight its commitment to developing innovative therapies, with plans for both oral and poster presentations. This event underscores Biohaven's advances in addressing diseases with high unmet medical needs.
Read more →BHVN▼ -13.8%on this news
Biohaven Reports Positive Degrader Data Achieving 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule...
Biohaven Ltd. reported promising findings from its Phase 1 study of BHV-1300, a potential first-in-class IgG degrader. The drug demonstrated rapid and sustained reductions in total IgG levels, achieving a median reduction of 80% and showing a favorable safety profile with no serious adverse events. BHV-1300 leverages the body’s natural clearance mechanisms and is designed for self-administration, marking a significant innovation in the treatment of autoimmune diseases such as Graves' disease. The company plans to advance BHV-1300 further in clinical development based on these positive results.
Read more →BHVN▼ -13.8%on this news
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in ...
Biohaven Ltd. reported its recent business developments and financial results for Q4 and full year 2024, highlighting significant progress in its drug portfolio. The FDA has accepted the NDA for troriluzole, signaling a potential breakthrough for patients with spinocerebellar ataxia. Financially, the company reported a cash position of approximately $489 million, indicating strong resources for ongoing and future clinical programs. However, their increased R&D expenses raise concerns about sustainability without future revenue from approved therapies.
Read more →BHVN▲ +11.2%on this news
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a...
Biohaven has announced that the FDA has accepted and granted Priority Review for its New Drug Application (NDA) for troriluzole, aimed at treating Spinocerebellar Ataxia (SCA), a rare neurodegenerative disease with no existing treatments. This decision was based on positive results from a multi-center study demonstrating that troriluzole significantly reduced disease progression and improved patient outcomes over three years. The acceptance highlights the urgency for new interventions in SCA, with the potential for widespread impact on patients' quality of life.
Read more →BHVNBiohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy Presents progress and new anticipated milestones across portfolio of more than 10 assets and 6 therapeutic areas. Announces multiple advancements...
Biohaven Ltd. showcased its progress and future milestones at the 43rd Annual J.P. Morgan Healthcare Conference. The company presented positive Phase 1 data for BHV-1400, an investigational therapy for IgA nephropathy, highlighting its potential to differentiate from existing treatments. Biohaven's broad portfolio includes several other programs across therapeutic areas, supported by FDA acceptance of multiple investigational new drugs. The advancements in their MoDE platform exemplify the company's aim to revolutionize treatment approaches for various diseases.
Read more →BHVNBiohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan...
Biohaven Ltd. (NYSE: BHVN) announced that CEO Vlad Coric will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The company is focused on developing innovative treatments in areas such as immunology, neuroscience, and oncology. Biohaven has a broad portfolio that includes drugs for conditions like epilepsy and migraine. However, the company has acknowledged substantial risks associated with their forward-looking statements regarding future developments.
Read more →BHVN▲ +7.7%on this news
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates BHV-1300 achieved deep lowering of targeted IgG, with reductions 60% in the lowest subcutaneous dose tested in the MAD. Subcutaneous BHV-1300...
Biohaven Ltd. announced significant advancements in its clinical programs, with promising Phase 1 results for BHV-1300, achieving over 60% reduction in targeted IgG at the lowest dose tested. The company also submitted a New Drug Application (NDA) for Troriluzole for treating spinocerebellar ataxia (SCA), showcasing its efficacy in slowing disease progression. Additionally, Biohaven is advancing its MoDE clinical program with ongoing human dosing for BHV-1400 and BHV-1600, targeting autoantibody-mediated diseases, and completed enrollment for the pivotal BHV-7000 trial in bipolar disorder.
Read more →BHVNBiohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting Reported expanded safety results from BHV-7000 Phase 1 multiple ascending dose studies, including the once-daily extended-release formulation being...
Biohaven Ltd. presented expanded safety data for BHV-7000 at the American Epilepsy Society 2024 Annual Meeting, showcasing excellent safety and tolerability. The once-daily extended-release formulation is currently evaluated in ongoing Phase 2 and 3 clinical studies. Findings indicate that BHV-7000 offers significant advantages over current anti-seizure medications, as it avoids common adverse effects. The company also discussed the ongoing pivotal trials addressing significant unmet needs in epilepsy treatment.
Read more →BHVNBiohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity In the RESILIENT SMA study, taldefgrobep alpha showed clinically meaningful improvements in motor function at all timepoints on the Motor Function...
Biohaven announced updates on its taldefgrobep alfa program for spinal muscular atrophy (SMA) and obesity, highlighting positive outcomes in the RESILIENT SMA study. While taldefgrobep demonstrated significant improvements in motor function among specific subgroups, the overall primary outcome did not reach statistical significance. Importantly, the drug exhibited favorable changes in body composition, suggesting its potential applicability for obesity treatment. The company plans to advance its clinical plans for taldefgrobep in Q4 2024 and engage with the FDA based on emerging data.
Read more →BHVNBiohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline...
Biohaven Ltd. announced its third quarter financial results for 2024, reporting a net loss of $160.3 million. The company highlighted positive topline results from a trial of troriluzole for spinocerebellar ataxia, indicating potential advancements in treatment. Financially, Biohaven is well-positioned with approximately $642 million in cash equivalents, despite a significant rise in research and development expenses due to ongoing clinical trials. The company anticipates reporting further updates across its diverse pipeline in the coming months.
Read more →BHVNBiohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Biohaven Ltd. has announced the completion of its public offering, which included the sale of 6,052,631 common shares at a price of $47.50 each. The offering also saw the full exercise of an option by underwriters for an additional 789,473 shares, bringing the total gross proceeds to approximately $287.5 million. The company plans to utilize the proceeds for general corporate purposes. Several prominent financial institutions acted as joint lead managers for the offering.
Read more →BHVNBiohaven Announces Pricing of $250 Million Public Offering of Common Shares Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Biohaven Ltd. has priced its public offering of 5,263,158 common shares at $47.50 per share, aiming to raise approximately $250 million. The offering is set to close on October 2, 2024, pending customary closing conditions. The proceeds will be utilized for general corporate purposes. Biohaven has granted underwriters an option to purchase additional shares, showing confidence in their funding strategy.
Read more →BHVNBiohaven Announces Proposed Public Offering of Common Shares Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Biohaven Ltd. has announced a proposed public offering of $250 million in common shares, which will be underwritten by J.P. Morgan and Morgan Stanley. The shares are subject to market conditions, and the company intends to use the proceeds for general corporate purposes. Furthermore, Biohaven may grant the underwriters an option to purchase an additional $37.5 million in shares. However, investors are advised about the risks and uncertainties associated with the offering's completion and timing.
Read more →BHVNBiohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent,...
Biohaven Ltd. has initiated a pivotal Phase 2 trial for its investigational drug BHV-2100, targeting acute migraine treatment. The trial will evaluate the efficacy and safety of two doses of BHV-2100, aiming to support FDA registration. This first-in-class TRPM3 antagonist has already shown promising safety in previous Phase 1 trials, with expectations to significantly relieve the burden of migraine for patients who do not respond to existing therapies. Approximately 575 patients will be enrolled across 60 sites in the U.S. for this study.
Read more →BHVN▲ +13.7%on this news· ran to +27% by day 3
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change
Biohaven announced positive topline results from its pivotal study of Troriluzole for Spinocerebellar Ataxia (SCA), demonstrating significant efficacy in slowing disease progression. The treatment achieved primary and secondary endpoints, showing a meaningful delay in decline compared to untreated patients. Biohaven plans to submit a New Drug Application to the FDA for Troriluzole in late 2024, leveraging its orphan drug and fast-track designations. The results signify a hopeful advancement in the treatment of a condition currently lacking approved therapies.
Read more →BHVNBiohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia Biohaven Ltd. (NYSE: BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE...
Biohaven Ltd. has announced a conference call scheduled for September 23, 2024, to discuss topline data from its pivotal study BHV4157-206-RWE, which focuses on the drug troriluzole as a treatment for Spinocerebellar Ataxia. This study was developed in collaboration with the FDA, suggesting a well-planned clinical approach. Troriluzole is a new chemical entity designed to modulate glutamate levels and may have broader therapeutic potential. The call will be accessible via the company's Investor Relations website.
Read more →BHVN▲ +5.9%on this news
Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024 Biohaven's Molecular Degrader...
Biohaven Ltd. reported its financial results for the second quarter of 2024, highlighting a cash position of approximately $440 million and significant advancements in its clinical pipeline. The company showcased promising developments across various therapeutic areas, including BHV-1300, which utilizes novel degrader technology. However, the financial results indicated a net loss of $319.8 million, marking a considerable increase from the previous year, primarily due to rising R&D expenses. Despite these challenges, Biohaven remains committed to its mission of delivering transformative therapies.
Read more →BHVN▼ -12.6%on this news
Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of...
Biohaven Ltd. presented updates on its innovative drug portfolio at the 2024 Investor R&D Day, highlighting positive interim data from its BHV-1300 Phase 1 study. The data indicates that BHV-1300 can significantly reduce IgG levels in a safe and well-tolerated manner. The company plans to evaluate this drug further in patients with rheumatoid arthritis and anticipates adding more clinical-stage degraders to its pipeline in the coming years. Other therapeutic areas discussed include neurology, metabolic disorders, and oncology.
Read more →BHVN▼ -12.6%on this news
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors -BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated ...
Biohaven Ltd. announced the dosing of the first patient in a Phase 1/2 clinical trial for its new antibody drug conjugate, BHV-1510. This treatment targets tumors expressing Trophoblast Cell Surface Antigen-2 (Trop-2) and aims to provide an effective option for advanced or metastatic epithelial tumors. The trial will explore BHV-1510 both as a monotherapy and in combination with Regeneron's anti-PD-1 therapy, Libtayo. With promising preclinical results, BHV-1510 could represent a significant advancement in the treatment of solid tumors.
Read more →BHVNBiohaven Reports First Quarter 2024 Financial Results and Recent Business Developments Cash, cash equivalents, marketable securities and restricted cash totaled approximately $287.6 million on March 31, 2024, which excludes the net...
Biohaven Ltd. has reported its financial results for Q1 2024, showcasing a cash position of $287.6 million to support ongoing clinical trials. The company highlighted positive advancements, including the initiation of a first-in-human study of BHV-1300 and ongoing developments across multiple therapeutic areas. However, a notable net loss of $179.5 million and increased research expenses presents challenges moving forward. The release details upcoming IND applications and ongoing trials in various drug development programs.
Read more →BHVNBiohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in...
Biohaven Ltd. announced the successful closing of its public offering of 6,451,220 shares, including the full exercise of an underwriter option for an additional 841,463 shares. The offering priced at $41.00 per share yielded gross proceeds of approximately $264.5 million. The funds will be used for general corporate purposes, potentially strengthening Biohaven's position in drug development. The company engaged multiple financial institutions to facilitate the offering and confirmed compliance with necessary regulatory filings.
Read more →BHVNBiohaven Announces Pricing of $230 Million Public Offering of Common Shares Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in...
Biohaven Ltd. has priced its public offering of 5,609,757 common shares at $41.00 each, aiming to raise approximately $230 million before expenses. The offering is set to close on April 22, 2024, pending customary closing conditions. Proceeds from the offering will be utilized for general corporate purposes. A group of leading financial institutions is managing the offering, which is being conducted under an effective shelf registration statement. Investors are warned about the risks associated with forward-looking statements regarding the completion and financial impact of the offering.
Read more →BHVNBiohaven Announces Proposed Public Offering of Common Shares Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in...
Biohaven Ltd. (NYSE: BHVN) announced a proposed public offering of $200 million in common shares, all of which will be sold by the company. Additionally, there is a possibility for the underwriters to purchase up to $30 million in additional shares. The proceeds from this offering are intended for general corporate purposes, but the completion of the offering is contingent upon market conditions. Investors are advised to review the prospectus and pertinent SEC filings for more details.
Read more →BHVN▼ -15.7%on this newsshared move
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300, was selected for an oral...
Biohaven Ltd. announced that it will feature 20 abstracts at the 2024 American Academy of Neurology Annual Meeting, including eight oral presentations and twelve posters. The event underscores Biohaven's advancements in neuroscience research, particularly in areas such as Kv7 ion channel modulation and TRPM3 antagonism. Notably, its BHV-2100 abstract received recognition as an AAN Abstract of Distinction in the pain category, reflecting the promising potential of this non-opioid pain treatment. The company is committed to developing innovative therapies for various neurological disorders, aiming to address significant unmet medical needs.
Read more →BHVNBiohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology:...
Biohaven Ltd. has reported its financial results for Q4 and FY 2023, showcasing significant advances in its innovative platforms focused on immunology, neuroscience, and oncology. The company is on track to deliver critical data from three key programs in the upcoming year, including first-in-human results for BHV-1300 and Phase 3 insights for its glutamate modulating agent, troriluzole. Biohaven is also exploring new avenues with its myostatin inhibitor, taldefgrobep alfa, which may aid in weight loss and spinal muscular atrophy treatment. Despite a strong financial position, concerns arise from ongoing high R&D expenses, highlighting the challenges ahead.
Read more →BHVN▲ +10.5%on this news
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Biohaven Ltd. presented its advances at the 42nd Annual J.P. Morgan Healthcare Conference, emphasizing progress in therapeutic programs focused on neuroscience, immunology, and oncology. The company highlighted promising products, including BHV-7000 for epilepsy and mood disorders, and its extracellular protein degradation platform targeting autoimmune diseases. With multiple anticipated clinical milestones in 2024, Biohaven aims to enhance patient care and drive shareholder value. CEO Vlad Coric expressed confidence in the company's strategic direction and innovative portfolio following its recent spinoff from Pfizer.
Read more →BHVNBiohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan...
Biohaven Ltd. (NYSE: BHVN) has announced that CEO Vlad Coric will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 8, 2024. This event showcases the company's innovative approach and commitment to developing therapies for a wide range of diseases. Biohaven's pipeline includes therapies targeting conditions like epilepsy, obsessive-compulsive disorder, and neuroinflammatory disorders. The presentation is expected to highlight the company's clinical advancements and future plans.
Read more →BHVNBiohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all...
Biohaven Ltd. presented expanded EEG and safety data for its drug BHV-7000 at the 2023 American Epilepsy Society Annual Meeting. The Phase 1 study demonstrated favorable safety and tolerability with doses up to 120 mg per day. BHV-7000's unique properties, including being a selective Kv7.2/7.3 activator, may offer advantages over existing epilepsy treatments. The findings highlight Biohaven's ongoing commitment to developing innovative therapies for epilepsy.
Read more →BHVNBiohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments Cash, cash equivalents, marketable securities and restricted cash totaled approximately $495 million on October 5, 2023, which included net proceeds...
Biohaven Ltd. reported its financial results for the third quarter of 2023, highlighting a cash position of approximately $495 million. The company announced significant progress in its clinical programs, particularly with BHV-1300 and BHV-7000, aimed at immunology and epilepsy treatment. Despite a substantial net loss of $102.6 million for the quarter, Biohaven is set to initiate a Phase 3 program for BHV-7000 before the end of the year, showcasing the potential of its drug pipeline. The ongoing enhancements in their development programs indicate a strategic commitment to innovate therapy for various diseases.
Read more →BHVNBiohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® - Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases...
Biohaven Ltd. presented promising preclinical data on taldefgrobep alfa at The Obesity Society's ObesityWeek conference. The novel myostatin inhibitor demonstrated the ability to significantly reduce fat mass while increasing lean mass in an obese mouse model. Additionally, the findings indicated that changes in waist circumference might be valuable alternative endpoints in obesity studies. A Phase 2 study for the drug is planned for 2024, highlighting its potential as a new therapy for obesity management.
Read more →BHVN▼ -7.5%on this newsshared move
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Biohaven Ltd. announced the pricing of a public offering of 10,227,273 common shares at a price of $22.00 per share, aiming to raise approximately $225 million. The offering includes an option for underwriters to purchase additional shares, expected to close on October 5, 2023. The proceeds will be used for general corporate purposes, although the completion of the offering is subject to customary closing conditions and certain risks.
Read more →BHVN▼ -7.5%on this newsshared move
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Biohaven Ltd. has announced a proposed public offering of $200 million in common shares, with an additional option for the underwriter to purchase up to $30 million more. The offering will be subject to market conditions, and there are no guarantees regarding its completion or terms. The funds raised will be used for general corporate purposes. Investors are advised to review a prospectus before participating in the offering, which carries inherent risks and uncertainties.
Read more →BHVN▼ -6.2%on this news
Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies Examination of EEG in healthy subjects administered single doses of BHV-7000 confirmed central nervous system (CNS) activity consistent with effects...
Biohaven Ltd. recently announced positive preliminary results from its exploratory Phase 1 electroencephalogram (EEG) biomarker study of BHV-7000. These results indicated effective central nervous system activity and are set to support upcoming Phase 3 studies in focal epilepsy targeting a pivotal trial initiation by the end of 2023. The data showed promising dose-dependent changes in EEG spectral power, akin to effects seen with other antiseizure medications, while maintaining a favorable safety profile. Following this study, Biohaven is also developing a new once-daily extended-release formulation of BHV-7000.
Read more →BHVNBiohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy Biohaven Ltd. (NYSE: BHVN; Biohaven ) announced today that it received orphan medicinal product designation from the European Commission (EC) for...
Biohaven Ltd. announced that its candidate taldefgrobep alfa has received orphan medicinal product designation from the European Commission for the treatment of spinal muscular atrophy (SMA). This designation signifies the potential for taldefgrobep to offer significant benefits for SMA patients, along with regulatory advantages such as reduced fees and extended market exclusivity. Biohaven is currently conducting a Phase 3 clinical trial to assess taldefgrobep's efficacy and safety for SMA patients, further highlighting its commitment to developing innovative therapies for rare diseases.
Read more →BHVNBiohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023 Announced positive interim data from BHV-7000 EEG...
Biohaven Ltd. released its financial results for Q2 2023, showcasing positive developments in drug candidates such as BHV-7000 and BHV-8000. The company reported a net loss of $90.3 million but holds $349 million in cash equivalents. There were significant advancements in various clinical trials, including plans for future studies in Parkinson’s disease and obesity. The company's leadership emphasized strong progress since its spin-off, highlighting the potential of their drug candidates without the adverse events typically associated with other treatments.
Read more →BHVNdevelopment, timing and potential marketing approval and commercialization of development candidates are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, de
Biohaven Ltd. provided updates on several key projects, including positive preliminary EEG data for its drug BHV-7000, indicating effective target engagement in the central nervous system. The company also reported favorable safety and tolerability results for BHV-8000 in Phase 1 studies. Despite these advancements, Biohaven faces a challenge with the FDA's refusal to review the NDA for troriluzole, citing concerns over unmet endpoints in clinical trials. The company plans to engage with the FDA to address these concerns, emphasizing the unmet need for treatment options in specific rare disorders.
Read more →BHVN▼ -22.6%on this newsshared move
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates Biohaven Ltd. (NYSE: BHVN) ( Biohaven or the Company ), a global clinical-stage biopharmaceutical company focused on the discovery, development and ...
Biohaven has provided updates on various clinical programs, including promising preliminary EEG data from BHV-7000 indicating efficacy without adverse CNS effects typically linked to antiseizure medications. Following positive outcomes in Phase 1 trials, the company plans to initiate pivotal studies in focal epilepsy and bipolar disorder later in 2023. Biohaven also reported favorable progress for other candidates, but faced a setback with the FDA's refusal to file the NDA for troriluzole due to unmet endpoints. The ongoing development of additional compounds like BHV-8000 and BHV-1300 continue to exhibit potential safety and pharmaceutical profiles.
Read more →BHVN▲ +7.6%on this news· ran to +33% by day 3
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day Submitted a new drug application (NDA) for troriluzole in Spinocerebellar Ataxia Type 3 (SCA3) to U.S. FDA in 2Q2023, marking the team's fourth NDA...
Biohaven Ltd. has provided an overview of its clinical advances, regulatory updates, and pipeline developments during an R&D Day event. The highlight includes the submission of a new drug application for troriluzole targeting Spinocerebellar Ataxia Type 3 (SCA3). The company emphasized its commitment to developing innovative therapies for brain disorders and acknowledged the support from patient advocacy groups in these endeavors. CEO Vlad Coric outlined the pivotal role of collaborative efforts in overcoming challenges associated with rare disease research.
Read more →BHVN▲ +7.6%on this news· ran to +33% by day 3
Investor Contact Jennifer Porcelli Vice President, Investor Relations jennifer.porcelli biohavenpharma.com +1 (201) 248-0741 Media Contact Mike Beyer Sam Brown Inc. mikebeyer sambrown.com +1 (312) 961-2502
Biohaven Ltd. has provided an overview of its clinical progress, regulatory updates, and pipeline developments during its R&D Day. The company announced the submission of a new drug application (NDA) for troriluzole, aimed at treating Spinocerebellar Ataxia Type 3 (SCA3), as well as updates on its Kv7 platform and various Phase 1 and Phase 3 trials. With multiple investigational New Drug (IND) applications planned, Biohaven demonstrates its commitment to developing therapies for rare neurological disorders, as emphasized by its executive leadership during the event.
Read more →BHVNBiohaven to Present R&D Day at Yale School of Management Biohaven Ltd. (NYSE: BHVN) ( Biohaven ), a global clinical-stage biopharmaceutical company focused on the discovery, development and...
Biohaven Ltd. (NYSE: BHVN) will host an R&D Day at Yale School of Management on May 31, coinciding with the Yale Ventures Innovation Summit 2023. The event will feature discussions led by Biohaven's senior management team and key opinion leaders, focusing on the company's platforms and pipeline, particularly therapies for debilitating diseases. Investors interested in attending are encouraged to reach out to Biohaven Investor Relations due to limited space.
Read more →BHVNBiohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global...
Biohaven Ltd. reported its financial results for Q1 2023, highlighting a net loss of $70.5 million while expressing optimism about its neuroscience pipeline. The company anticipates significant milestones with projects like BHV-7000 and the new TYK2/JAK1 platform. CEO Vlad Coric emphasized the company's focus on addressing critical patient needs and advancing toward important regulatory submissions. Despite financial losses, ongoing initiatives reflect Biohaven's commitment to innovation in treatment development for neurological disorders.
Read more →BHVN▲ +9%on this news
Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy Biohaven Ltd. (NYSE: BHVN) ( Biohaven ), a global clinical-stage biopharmaceutical company, today announced that Nick Kozauer, M.D. has joined its...
Biohaven Ltd. announced the appointment of Nick Kozauer, M.D. as Senior Vice President for Clinical Development and Regulatory Strategy. Kozauer joins Biohaven from the FDA where he led the regulation of various neurology-related drug applications. His experience is anticipated to enhance Biohaven's capacity to advance its pipeline in neuroscience and develop new therapies targeting high unmet medical needs. The appointment reflects Biohaven's ongoing commitment to improving patient care in the field of neuroimmunology and other neurological disorders.
Read more →BHVNBiohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global...
Biohaven Ltd. reported its fourth quarter and full year 2022 financial results and highlighted recent milestones. The company, recently acquired by Pfizer, is focused on advancing a robust portfolio, including innovative treatments for neurological disorders. Key developments include the Kv7 platform aimed at epilepsy and mood disorders, along with an exclusive license for a dual TYK2/JAK1 inhibitor for brain conditions. Upcoming studies and IND submissions are anticipated throughout 2023 as Biohaven continues to capitalize on its strengthened capital position and extensive pipeline.
Read more →BHVN▲ +5.3%on this news· ran to +25% by day 3
januaryinvesto 41st Annual J.P. Morgan Healthcare Conference Vlad Coric, M.D., Chairman and Chief Executive Officer
During the 41st Annual J.P. Morgan Healthcare Conference, Biohaven Ltd.'s CEO, Vlad Coric, discussed the company's pipeline and development programs, highlighting multiple product candidates, including BHV-7000. The presentation emphasized the successful completion of Phase I trials for BHV-7000, indicating positive safety profiles and potential therapeutic benefits. The focus is on advancing treatment options for neurological and neuropsychiatric diseases, as well as plans for further studies and regulatory actions in 2023.
Read more →BHVNBiohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares Biohaven Ltd. (NYSE: BHVN) (the Company or Biohaven ) today announced the closing of an underwritten public offering of 28,750,000 of its common...
NEW HAVEN, Conn. , Oct. 25, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN ) (the "Company" or "Biohaven") today announced the closing of an underwritten public offering of 28,750,000 of its common shares, which includes the full exercise of the underwriters' option to purchase 3
Read more →BHVNBiohaven Advances Development of the MoDE Platform Technology Licensed From Yale University Biohaven advances development of its extracellular target degrader platform technology (MoDEs™) for therapies across a variety of diseases including...
NEW HAVEN, Conn. , Oct. 25, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN ; "Biohaven") today announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not
Read more →BHVNBiohaven Announces Launch of Public Offering of Common Shares Biohaven Ltd. (NYSE: BHVN) ( Biohaven ) announced today that it has commenced a public offering of 20,000,000 of its common shares pursuant to a...
NEW HAVEN, Conn. , Oct. 18, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN ) ("Biohaven") announced today that it has commenced a public offering of 20,000,000 of its common shares pursuant to a registration statement on Form S-1 (the "Registration Statement") filed with the Secu
Read more →Competitive Position
How BHVN ranks across every disease it competes inCompetitive Position is a premium feature
See how BHVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial